OCS: Oculis Holding AG Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 820.63
Enterprise Value ($M) n/a
Book Value ($M) 73.38
Book Value / Share 1.39
Price / Book n/a
NCAV ($M) 57.93
NCAV / Share 1.09
Price / NCAV n/a

Profitability (mra)
Return on Invested Capital (ROIC) -1.15
Return on Assets (ROA) -0.87
Return on Equity (ROE) -1.09

Liquidity (mrq)
Quick Ratio 2.37
Current Ratio 2.37

Balance Sheet (mrq) ($M)
Current Assets 104.90
Assets 120.35
Liabilities 46.97
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.69
Operating Income -73.20
Net Income -85.78

Cash Flow Statement (mra) ($M)
Cash From Operations -47.50
Cash from Investing -17.56
Cash from Financing 54.03

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-12 13G/A LSP 7 Cooperative UA 13.80 7.99
02-11 13G/A Bvcf Iv, L.p. 5.05 5.88
01-03 13G/A Brunnur vaxtarsjodur slhf 0.00 -100.00
12-09 13G Pivotal bioVenture Partners Fund I, L.P. 5.20 6.98

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-07 17,065 173,018 9.86
2025-04-04 15,334 95,039 16.13
2025-04-03 3,262 35,665 9.15
2025-04-02 3,343 45,309 7.38

(click for more detail)

Similar Companies
NGNE – Neurogene Inc. NRIX – Nurix Therapeutics, Inc.
NTLA – Intellia Therapeutics, Inc. OCUL – Ocular Therapeutix, Inc.
OKUR – OnKure Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io